F m Investments LLC Makes New Investment in Trevi Therapeutics, Inc. $TRVI

F m Investments LLC bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the 4th quarter, Holdings Channel reports. The institutional investor bought 241,483 shares of the company’s stock, valued at approximately $3,023,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Rubric Capital Management LP boosted its holdings in Trevi Therapeutics by 88.0% in the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after acquiring an additional 3,993,325 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Trevi Therapeutics by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 6,434,655 shares of the company’s stock worth $80,562,000 after acquiring an additional 607,669 shares in the last quarter. Viking Global Investors LP boosted its holdings in Trevi Therapeutics by 232.4% in the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock worth $46,929,000 after acquiring an additional 3,585,875 shares in the last quarter. Vivo Capital LLC boosted its holdings in Trevi Therapeutics by 13.5% in the third quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock worth $46,616,000 after acquiring an additional 606,765 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Trevi Therapeutics by 95.4% in the third quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock worth $44,302,000 after acquiring an additional 2,363,835 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Key Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: HC Wainwright lifted near-term EPS estimates for Q2 2026 to ($0.11) from ($0.12), suggesting modestly better expected profitability. Trevi Therapeutics Q1 2026 Earnings Call Transcript
• Positive Sentiment: The firm also increased its Q3 2026 EPS estimate to ($0.14) from ($0.17), Q4 2026 to ($0.15) from ($0.17), and FY2026 to ($0.47) from ($0.54).
• Positive Sentiment: HC Wainwright kept a bullish long-term view, raising its FY2027 estimate to ($0.57) from ($0.63) and FY2028 to ($0.63) from ($0.66), while maintaining the same $21 price target.
• Neutral Sentiment: The analyst trimmed its FY2029 estimate to $0.70 from $0.79 in one report, but the overall tone remained constructive.
• Neutral Sentiment: Trevi recently reported a Q1 loss of ($0.09) per share, slightly wider than expectations, so the stock’s move appears driven more by improved forward estimates and analyst confidence than by the latest earnings print.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $14.50 on Friday. Trevi Therapeutics, Inc. has a one year low of $5.38 and a one year high of $16.12. The stock has a market capitalization of $2.06 billion, a PE ratio of -45.31 and a beta of 1.07. The business’s fifty day moving average is $12.69 and its 200 day moving average is $11.95.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen cut Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.90.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.